临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1118567-05-7

Bexagliflozin (EGT1442)

中文名称:贝沙格列净
CAS号:1118567-05-7
分子式: C24H29ClO7 分子量: 464.94
产品形式: Free Base
研发状态: Withdrawn
研发用途: Type 2 Diabetes Mellitus
研究机构: Theracos
研发日期: August 1 2018
研发阶段: Phase 1
Bexagliflozin (EGT1442, EGT-0001442, THR-1442) is a potent and selective SGLT2 inhibitor with an IC50 of 2 nM.

CAS: 111406-87-2

Zileuton (A-64077)

中文名称:齐留通
CAS号:111406-87-2
分子式: C11H12N2O2S 分子量: 236.29
产品形式: free base
研发状态: Completed
研发用途: Sickle Cell Disease
研究机构: Children''s Hospital Medical Center Cincinnati
研发日期: Sep-10
研发阶段: Phase 1
Zileuton (A-64077, Abbott 64077, ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used to decrease the symptoms of asthma. Zileuton induces apoptosis while inhibits ferroptosis.

CAS: 1110813-31-4

Dacomitinib (PF-00299804)

中文名称:达克替尼
CAS号:1110813-31-4
分子式: C24H25ClFN5O2 分子量: 469.94
产品形式: free base
研发状态: Not yet recruiting
研发用途: Carcinoma Non-Small-Cell Lung
研究机构: Pfizer
研发日期: September 1 2024
研发阶段: --
Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.

CAS: 1110766-97-6

Lusutrombopag

中文名称:卢曲波帕
CAS号:1110766-97-6
分子式: C29H32Cl2N2O5S 分子量: 591.55
产品形式: Free Base
研发状态: Completed
研发用途: Chronic Liver Disease; Thrombocytopenia
研究机构: Shionogi; Shionogi Inc.
研发日期: June 15 2015
研发阶段: Phase 3
Lusutrombopag (Mulpleta, S-888711) is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).

CAS: 111025-46-8

Pioglitazone (AD-4833)

中文名称:匹格列酮
CAS号:111025-46-8
分子式: C19H20N2O3S 分子量: 356.44
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: ANCA Associated Vasculitis; Rapidly Progressive Glomerulonephritis; Crescentic Glomerulonephritis
研究机构: Assistance Publique - Hôpitaux de Paris; Ministry of Health France
研发日期: Jul-23
研发阶段: Phase 3
Pioglitazone (AD-4833, U 72107) is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ.

CAS: 111-02-4

Squalene

中文名称:角鲨烯
CAS号:111-02-4
分子式: C30H50 分子量: 410.72
产品形式: free base
研发状态: Completed
研发用途: Essential Fatty Acid Deficiency (EFAD)
研究机构: Baxter Healthcare Corporation
研发日期: January 22 2021
研发阶段: Phase 4
Squalene (Spinacene, Supraene, trans-Squalene), a naturally occurring substance found in plants, animals and humans, is a component of some adjuvants that is added to vaccines to enhance the immune response.